1174P RESUNET (GETNE-2016-01): A phase II study to evaluate the efficacy and safety of the rechallenge with sunitinib in G1/G2 pancreatic neuroendocrine tumours (pNET). A Spanish Task Force Group in neuroendocrine and endocrine tumours (GETNE) study
Authors:
- 1 September 2020
- journal article
- abstracts
- Published by Elsevier in Annals of Oncology
- Vol. 31, S777-S778